2017-08-24T05:05:39-07:00 2016-12-31 C DeWitt Foard & Co PA CPAs 817 E Morehead Street Ste 100 Charlotte NC 282022767 990 2016-01-01 562174163 The Jeff Gordon Childrens Foundation JEFF 9809995150 1310 S Tryon Street Charlotte NC 28203 Jeffery M Gordon President 2017-08-24 true Phillip G Wilson P00096084 7043721515 2016 2021-01-29 14:40:06Z Jeffery M Gordon 4325 Papa Joe Hendrick Blvd Charlotte NC 28262 1375269 false false X www.jeffgordonchildrensfoundation.org X 1999 NC The organization's primary mission is to support children battling cancer by funding programs that improve patients' quality of life, treatment programs that increase survivorship, and pediatric medical research dedicated to finding a cure. 6 5 0 380 0 1615554 803499 0 12909 3870 627298 485623 2255761 1292992 1481286 1229816 0 349517 357230 0 307000 483683 404411 2314486 1991457 -58725 -698465 885252 1890611 1610059 885252 280552 X The organization's primary mission is to support children battling cancer by funding programs that improve patients' quality of life, treatment programs that increase survivorship, and pediatric medical research dedicated to finding a cure. false false 582686 500000 Riley Childrens Hospital/ Indiana University Department of PediatricsThe goal of the program is to continue to train the next generation of precision medicine oncology-focused pediatric physician scientists and translational scientists, thereby ensuring children with cancer receive the latest medical treatments. We propose to train junior faculty and pediatric oncology fellows to develop the knowledge and skills to become independent, productive physician scientists as academic pediatricians focused on improving child and adolescent health.The program provides structured research, mentorship, protected research time, and career development programs for the most highly qualified fellows and junior faculty. 301404 258741 Childrens Oncology GroupProject:EveryChild Recent studies suggest that circulating tumor DNA is present in the plasma of solid tumor patients at diagnosis. This circulating tumor DNA may provide a basis for early detection or as a baseline for disease monitoring during treatment. COG will collect samples at diagnosis using special tubes (Streck tubes) which allow for the collection of circulating tumor DNA. The Streck tubes will be processed for plasma and white blood cells (WBCs) for future extraction of circulating DNA and tumor DNA, respectively. 281002 241183 Childrens National Health SystemThe study seeks to generate custom gene-fusion databases including all possible fusion events present in a tumors DNA. This database will be used to map all of the proteins that have been sequenced in the same tumor. Doing so will enable the team to assign protein fragments that do not correspond to the reference genome to disease-specific genomic structural variations, thereby validating those that are capable of effecting cellular change.By continuing this line of inquiry, the team aims to identify genetic events that transform normal cells into tumor progenitors including gene fusions and other structural variations leading to unique tumor proteins. In addition, they plan to leverage these unique tumor specific events to create assays to detect tumor DNA that is free floating in blood and cerebrospinal fluid. These personalized biomarkers could be used to monitor the effectiveness of therapy and detect early tumor recurrence at molecular resolution. Such a tool would allow an oncologist to precisely design a treatment regimen to avoid unnecessary toxicities while maintaining effectiveness. 267883 229892 1432975 true true false false false false false false false false true false false false true true true false false false false false false false false true false true false false false false false false false false false false false false true true false false false false false false false false false true 10 1 true 0 false false false false false false false false false 0 false false false false false false false false false false X 6 5 false false false false false false false true true false false true true true true false true true true false AK AL AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NV NY OH OR PA RI SC TN UT VA WA WI WV X X Ryan Hutcheson 9809995145 1310 S Tryon Street Charlotte NC 28203 Jeffery M Gordon President 0.50 0.00 X X 0 0 0 Jeffrey W Chell MD Director 1.00 0.00 X 0 0 0 Rick Hendrick Director 0.25 0.00 X 0 0 0 D Wade Clapp MD Director 1.00 0.00 X 0 0 0 James Reichard Director 0.25 0.00 X 0 0 0 Glenn Schineller Chairman 1.00 0.00 X 0 0 0 Patricia Kriger Executive Dir. 40.00 0.00 X 94500 0 0 Ryan Hutcheson CFO 4.00 0.00 X 8750 0 0 103250 0 false false false 0 803499 59559 803499 0 4406 4406 0 0 0 2364 2900 -536 -536 -536 0 565000 79377 485623 485623 0 0 1292992 489493 1229816 1229816 0 0 0 103250 61425 27650 14175 0 196236 45591 40607 110038 16390 5954 3798 6638 21317 7746 4940 8631 20037 7279 4643 8115 0 2614 2614 12601 12601 0 0 3845 3845 72747 4908 47576 20263 19862 7216 4602 8044 9468 3440 2194 3834 0 0 59828 21736 13863 24229 34251 22263 3425 8563 0 0 0 0 7737 2811 1793 3133 2903 2903 Event Expenses 68791 68791 Bank charges 27775 24325 3450 Dues & subscriptions 24167 24167 Communications 15250 5442 3471 6337 42572 7348 22465 12759 1991457 1432975 251482 307000 617330 1472099 0 10692 0 0 0 0 0 1697 90702 60750 31214 29952 236708 376171 0 0 0 0 885252 1890611 403135 1206924 0 1610059 X 870267 264735 14985 15817 885252 280552 885252 1890611 -698465 25433 68332 X false true X false false X 1297726 1577068 1337418 1615554 768707 6596473 0 0 1297726 1577068 1337418 1615554 768707 6596473 2089568 4506905 4036 15243 7433 6699 4406 37817 0 544828 617633 718398 712300 565000 3158159 9792449 0.46020 0.44880 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15156 2687 12469 75546 58063 17483 29952 Grants payable 1206924 1206924 X 1279788 25433 25433 1254355 3845 34792 38637 1292992 1966114 1966114 3845 21498 25343 1991457 Part X : FIN48 Footnote N/A Part XI, Line 4b: Other revenue amounts included on 990 but not included in F/S Section 481(a) adjustment $34792 Part XII, Line 4b: Other revenue amounts included on 990 but not included in F/S Section 481(a) adjustment $21498 false false false 565000 79377 false 565000 79377 79377 485623 MS MO NC OH WY true false true false 1.00000 Patricia Kriger 1310 S Tryon Street Suite 105 Charlotte NC 28203 false false true Childrens Natl Health System 111 Michigan Ave NW Washington DC 20010 521640403 501(c)(3) 241183 0 DNA identification program Childrens Oncology Group Fdn 3501 Civic Center Blvd Philadelphia PA 19104 453083156 501(c)(3) 258741 0 Project EveryChild database Memorial Sloan Kettering Ctr 885 Second Ave 8th Floor New York NY 10017 131924236 501(c)(3) 202000 0 SADA Drug Delivery Platform Partners in Health 800 Boylston St Suite 1400 Boston MA 02199 043567502 501(c)(3) 0 7424 Cost Handcrafted quilts Quilts for pediatric cancerpatients Riley Childrens Hospital 30 South Meridian St Ste 200 Indianapolis IN 46204 350868147 501(c)(3) 500000 0 Pediatric Oncology training Tatums Bags of Fun 1341 Kirkham Lane Indiapolis IN 46260 455268324 501(c)(3) 10000 0 Provide personal items for patients 6 0 Jeff Gordon Inc Owner 356605 Reimbursements false JG Real Property LLC Owner 42000 Rent false Schedule L, Part V Supplemental Information The Foundation reimburses Jeff Gordon, Inc., an entity owned by Jeffery M.Gordon, for the cost of certain salaries, employee benefits and operating expenses such as telephone, legal fees, etc. provided on its behalf. The Foundation has a triple net rental agreement with JG Real Property, LLC, an entity related through common control, whereby JG Real Property, LLC is the lessor and the Foundation is the lessee for office space. The lease agreement requires monthly rent payments of $3,075 from September 1, 2015 through December 31, 2020. During the year ended December 31, 2016, the Foundation paid JG Real Property, LLC $42,000 in rent payments. X 1 59559 false false false Client Note 1 Client Note 1 - Related Party Payroll Administrator All of Foundation's staff is employed directly by Jeff Gordon, Inc. as disclosed in Schedule L. This relationship exists in order to miminize overall payroll and related benefit costs incurred by the Foundation. Form 990, Part III, Line 4d: Other Program Services Description OTHER PROGRAM SERVICES 4: OTHER PROGRAM SERVICES 5: Memorial Sloan Kettering Cancer CenterNeuroblastoma frequently is only diagnosed after the disease has spread from the primary tumor site to multiple metastatic sites. This typically requires systemic chemotherapy affecting all parts of the body leading to unintended side effects. In the past recurrent metastatic neuroblastoma was treated with high doses of toxic chemotherapy requiring bone marrow transplant rescue due to the destruction of the patients blood producing bone marrow. These unintended off-target toxicities are well known even with todays precision medicines. Some of these toxicities could be life-long. The ultimate goal of drug development is to find a way to deliver medicine selectively to tumor cells, and not to normal bone marrow, the immune system, kidney, or other vital organs. The team has recently developed a system whereby we can control drug delivery with such precision that toxicity only occurs where the drug is picked up by tumor cells. This Self-assembly/Disassembly (SADA) therapeutic is composed of a multimeric bispecific antibody (BsAb) fragments that can bind to surface antigens on tumor cells and radioactive payload. These BsAbs fragment were engineered to spontaneously assemble into a multimeric SADA complex. Due to its multimeric nature, the SADA complex has enhanced cooperative binding (avidity) to the tumor target, increasing specificity to the target cells or tissues and extending initial serum half-life, while reducing non-specific binding to bystander targets and decreasing toxicity. At non-tumor sites, the SADA complex can spontaneously disassemble into smaller fragments which allow for rapid renal clearance from the body. Form 990, Part VI, Line 11b: Form 990 Review Process A copy of the Form 990 is provided to the Chief Financial Officer and it is reviewed and approved by the Board prior to filing. Form 990, Part VI, Line 12c: Explanation of Monitoring and Enforcement of Conflicts Each director, principal officer and member of a committee with governing board delegated powers shall annually sign a statement which affirms such person:a. Has received a copy of the conflicts of interest policy,b. Has read and understands the policy,c. Has agreed to comply with the policy, andd. Understands the Foundation is charitable and in order to maintain its federal tax exemption it must engage primarily in activities which accomplish one or more of its tax exempt purposes. Form 990, Part VI, Line 15a: Compensation Review & Approval Process - CEO, Top Management The President and the Board of Directors Chairman review salaries and bonuses. Form 990, Part VI, Line 19: Other Organization Documents Publicly Available The Annual Report is available on the Organization's website.